Author

K. H. Pearce

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Approach:comparative / phylogenetic analysis· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

N. J. Moorman· 3 shared A. C. Puhl· 2 shared B. L. Hurst· 2 shared B. Yount· 2 shared E. J. Fritch· 2 shared F. Scholle· 2 shared J. A. Levi· 2 shared L. Premkumar· 2 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

N. J. Moorman

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Discovery of a cell-active chikungunya virus nsP2 protease inhibitor using a covalent fragment-based screening approach

E. M. Merten, J. D. Sears, T. M. Leisner, P. B. Hardy, A. Ghoshal, M. A. Hossain, K. H. Asressu, P. J. Brown, M. A. Stashko, L. E. Herring, A. L. Mordant, T. S. Webb, C. A. Mills, N. K. Barker, J. J. Arnold, , K. H. Pearce

This paper identifies and characterizes RA-0002034, a covalent inhibitor of CHIKV nsP2 protease, showing potent inhibition and selectivity against alphaviruses.

bioRxiv · Mar 22, 2024 · PreprintBiochemistry

Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice

A. C. Puhl, G. F. Gomes, S. Damasceno, E. J. Fritch, J. A. Levi, N. J. Johnson, F. Scholle, L. Premkumar, B. L. Hurst, F. LeeMontiel, F. P. Veras, S. S. Batah, A. T. Fabro, N. J. Moorman, B. Yount, , S. Ekins

This study tests FDA-approved kinase inhibitors against SARS-CoV-2 in vitro and in vivo, finding that vandetanib reduces inflammatory cytokines and mitigates lung inflammation in infected mice without reducing viral load.

bioRxiv · Dec 16, 2021 · PreprintImmunology

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms

A. C. Puhl, E. J. Fritch, T. R. Lane, L. V. Tse, B. Yount, C. Q. Sacramento, T. A. Tavella, F. T. M. Costa, S. Weston, J. Logue, M. Frieman, L. Premkumar, K. H. Pearce, B. L. Hurst, C. H. Andrade, , S. Ekins

This study evaluates the in vitro antiviral activity of three Ebola and Marburg virus inhibitors against SARS-CoV-2 and explores their potential mechanisms of action.

bioRxiv · Dec 1, 2020Pharmacology & Toxicology